Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges.
about
Phase I trials of antitumour agents: fundamental conceptsDesigns of drug-combination phase I trials in oncology: a systematic review of the literatureSeamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine.Adaptive designs for identifying optimal biological dose for molecularly targeted agents.All-comers versus enrichment design strategy in phase II trials.Innovations for phase I dose-finding designs in pediatric oncology clinical trials.A robust Bayesian dose-finding design for phase I/II clinical trials.Adaptive designs for dual-agent phase I dose-escalation studies.The changing landscape of phase I trials in oncology.An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials.Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities.A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacy.Bayesian model averaging continual reassessment method for bivariate binary efficacy and toxicity outcomes in phase I oncology trials.Bayesian procedures for phase I/II clinical trials investigating the safety and efficacy of drug combinations.STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.Dose finding with continuous outcome in phase I oncology trials.A Dose-Finding Method Based on Multiple Dosing in Two-Agent Combination Phase I Trials.A Bayesian dose-finding design for drug combination clinical trials based on the logistic model.Competing designs for drug combination in phase I dose-finding clinical trials.A pragmatic dose-finding approach using short-term surrogate efficacy outcomes to evaluate binary efficacy and toxicity outcomes in phase I cancer clinical trials.
P2860
Q26865346-9A9B28B7-2D73-4ECA-81E6-59E87FEEA168Q26996348-295EA7E5-2BA0-45D5-B83B-5A1FE617335CQ30371414-01970F80-CE8E-40EC-8C2A-4B4D55B537D0Q34535243-AC7D2664-01CD-4B5C-B7DE-5098FF906AD8Q34550826-51A038CA-FE0E-495C-B624-26467E15297DQ34857268-B372A8B6-AAF4-4DC2-9648-A2B0D5B322ECQ36757843-18F70A08-55F8-45B7-9C65-D46573FC0E5AQ37220245-354AA114-C197-486D-B32F-1F06C182A9D7Q38090897-F67371DD-4189-47B7-A496-82E5FAE7A612Q38629203-8B395F99-4E7C-4AED-87B0-BB7A2A6571CDQ38735192-642638E4-AC0A-422F-BE91-4154AC2F329DQ38753955-3883FC7C-C512-46EE-A05A-33DF2086B35FQ42434332-431513A5-DEDA-4CF7-9B08-5ADD259CF498Q43782645-E224745D-AA1C-49CA-83E8-FFA8D48C0FF5Q44002670-AEFE5A50-0215-49F7-84F6-5B3F8850CB31Q48275752-2DF1C25A-9DFD-4AF4-8D50-8E6F874A4BB1Q51010190-D906CA44-1706-436E-B3D9-5335F67F4505Q51016744-7E4E9F4D-4DC5-4E4A-983D-6D2181176FC5Q51086024-7E8C72A3-B9C4-4284-9CEA-126347F928FCQ51119546-C33A34E7-4ADE-4696-9627-0E95F3A735EEQ53125990-60098B46-67FF-4391-BA25-01AD356AA812
P2860
Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Model-based phase I designs in ...... tions: methods and challenges.
@en
Model-based phase I designs in ...... tions: methods and challenges.
@nl
type
label
Model-based phase I designs in ...... tions: methods and challenges.
@en
Model-based phase I designs in ...... tions: methods and challenges.
@nl
prefLabel
Model-based phase I designs in ...... tions: methods and challenges.
@en
Model-based phase I designs in ...... tions: methods and challenges.
@nl
P2093
P2860
P356
P1476
Model-based phase I designs in ...... tions: methods and challenges.
@en
P2093
Daniel J Sargent
Sumithra J Mandrekar
P2860
P304
P356
10.1002/SIM.3706
P407
P577
2010-05-01T00:00:00Z